Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab
Gastric cancer (GC) represents one of the most fatal neoplasms in gastrointestinal oncology and affected patients can only hope for cure in limited disease. In a metastatic situation however, patients have a worse prognosis finally resulting in cancer-related death. Some improvements were made by us...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2022-02-01
|
| Series: | Case Reports in Gastroenterology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/520057 |
| _version_ | 1818534859761516544 |
|---|---|
| author | Sebastian Schade Ute Koenig Ardian Mekolli Jochen Gaedcke Albrecht Neesse Johanna Reinecke Marius Brunner Ali Seif Amir Hosseini Julia Kitz Philipp Stroebel Joachim Lotz Michael Ghadimi Volker Ellenrieder Alexander Koenig |
| author_facet | Sebastian Schade Ute Koenig Ardian Mekolli Jochen Gaedcke Albrecht Neesse Johanna Reinecke Marius Brunner Ali Seif Amir Hosseini Julia Kitz Philipp Stroebel Joachim Lotz Michael Ghadimi Volker Ellenrieder Alexander Koenig |
| author_sort | Sebastian Schade |
| collection | DOAJ |
| description | Gastric cancer (GC) represents one of the most fatal neoplasms in gastrointestinal oncology and affected patients can only hope for cure in limited disease. In a metastatic situation however, patients have a worse prognosis finally resulting in cancer-related death. Some improvements were made by using intensified chemotherapy such as the FLOT protocol (5-FU, leucovorin, oxaliplatin and docetaxel). However, a breakthrough in the treatment of advanced GC has been achieved by pre-therapeutical tumor analysis for potentially targetable alterations. Microsatellite instability, PD-L1 expression, Epstein Barr virus, and human epidermal growth factor receptor-2 (HER2) overexpression or amplification are the most beneficial targets, if addressed, can prolong survival in a palliative situation. Whether the combination of these targeted therapeutics with chemotherapy can bring long-term survival or even a chance of cure in a metastatic situation is not clear. Here, we report the case of a 30-year-old man with GC and extensive metastases who was cured by anti-HER2 antibody Trastuzumab combined with the FLOT regime. Initial staging showed an exophytic Siewert type III tumor and extensive hepatic metastases. Histology resulted in gastric adenocarcinoma with HER2 overexpression (2+, FISH positive). Twelve courses of chemotherapy comprising Trastuzumab and FLOT were administered. After treatment, the extensive liver metastases had disappeared with no evidence of residual tumor growth on the CT scans. Monotherapy of Trastuzumab was continued until gastrectomy with D2 lymph node dissection and probing of liver tissue, which revealed no residual tumor cells. Five years after surgery, there is continued complete remission. In conclusion, Trastuzumab in combination with FLOT may have curative potential even for metastatic stages of HER-2-positive GC. |
| first_indexed | 2024-12-11T18:17:05Z |
| format | Article |
| id | doaj.art-46b5a7f78d744bb6883a145d5f8e4475 |
| institution | Directory Open Access Journal |
| issn | 1662-0631 |
| language | English |
| last_indexed | 2024-12-11T18:17:05Z |
| publishDate | 2022-02-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Gastroenterology |
| spelling | doaj.art-46b5a7f78d744bb6883a145d5f8e44752022-12-22T00:55:23ZengKarger PublishersCase Reports in Gastroenterology1662-06312022-02-01161808810.1159/000520057520057Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and TrastuzumabSebastian Schade0https://orcid.org/0000-0002-6316-6804Ute Koenig1Ardian Mekolli2Jochen Gaedcke3https://orcid.org/0000-0002-6130-5874Albrecht Neesse4Johanna Reinecke5Marius Brunner6Ali Seif Amir Hosseini7Julia Kitz8Philipp Stroebel9Joachim Lotz10Michael Ghadimi11Volker Ellenrieder12Alexander Koenig13Department of Clinical Neurophysiology, University Medical Center, Goettingen, GermanyDepartment of Gastroenterology and Gastrointestinal Oncology, University Medical Center, Goettingen, GermanyDepartment of Gastroenterology and Gastrointestinal Oncology, University Medical Center, Goettingen, GermanyDepartment of General-, Visceral- and Pediatric Surgery, University Medical Center, Goettingen, GermanyDepartment of Gastroenterology and Gastrointestinal Oncology, University Medical Center, Goettingen, GermanyDepartment of Gastroenterology and Gastrointestinal Oncology, University Medical Center, Goettingen, GermanyDepartment of Gastroenterology and Gastrointestinal Oncology, University Medical Center, Goettingen, GermanyDepartment of Diagnostic and Interventional Radiology, University Medical Center, Goettingen, GermanyInstitute of Pathology, University Medical Center, Goettingen, GermanyInstitute of Pathology, University Medical Center, Goettingen, GermanyDepartment of Diagnostic and Interventional Radiology, University Medical Center, Goettingen, GermanyDepartment of General-, Visceral- and Pediatric Surgery, University Medical Center, Goettingen, GermanyDepartment of Gastroenterology and Gastrointestinal Oncology, University Medical Center, Goettingen, GermanyDepartment of Gastroenterology and Gastrointestinal Oncology, University Medical Center, Goettingen, GermanyGastric cancer (GC) represents one of the most fatal neoplasms in gastrointestinal oncology and affected patients can only hope for cure in limited disease. In a metastatic situation however, patients have a worse prognosis finally resulting in cancer-related death. Some improvements were made by using intensified chemotherapy such as the FLOT protocol (5-FU, leucovorin, oxaliplatin and docetaxel). However, a breakthrough in the treatment of advanced GC has been achieved by pre-therapeutical tumor analysis for potentially targetable alterations. Microsatellite instability, PD-L1 expression, Epstein Barr virus, and human epidermal growth factor receptor-2 (HER2) overexpression or amplification are the most beneficial targets, if addressed, can prolong survival in a palliative situation. Whether the combination of these targeted therapeutics with chemotherapy can bring long-term survival or even a chance of cure in a metastatic situation is not clear. Here, we report the case of a 30-year-old man with GC and extensive metastases who was cured by anti-HER2 antibody Trastuzumab combined with the FLOT regime. Initial staging showed an exophytic Siewert type III tumor and extensive hepatic metastases. Histology resulted in gastric adenocarcinoma with HER2 overexpression (2+, FISH positive). Twelve courses of chemotherapy comprising Trastuzumab and FLOT were administered. After treatment, the extensive liver metastases had disappeared with no evidence of residual tumor growth on the CT scans. Monotherapy of Trastuzumab was continued until gastrectomy with D2 lymph node dissection and probing of liver tissue, which revealed no residual tumor cells. Five years after surgery, there is continued complete remission. In conclusion, Trastuzumab in combination with FLOT may have curative potential even for metastatic stages of HER-2-positive GC.https://www.karger.com/Article/FullText/520057advanced gastric cancerher2/neutrastuzumabtreatment strategies |
| spellingShingle | Sebastian Schade Ute Koenig Ardian Mekolli Jochen Gaedcke Albrecht Neesse Johanna Reinecke Marius Brunner Ali Seif Amir Hosseini Julia Kitz Philipp Stroebel Joachim Lotz Michael Ghadimi Volker Ellenrieder Alexander Koenig Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab Case Reports in Gastroenterology advanced gastric cancer her2/neu trastuzumab treatment strategies |
| title | Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab |
| title_full | Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab |
| title_fullStr | Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab |
| title_full_unstemmed | Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab |
| title_short | Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab |
| title_sort | cure is possible extensively metastatic her2 positive gastric carcinoma with 5 years of complete remission after therapy with the flot regimen and trastuzumab |
| topic | advanced gastric cancer her2/neu trastuzumab treatment strategies |
| url | https://www.karger.com/Article/FullText/520057 |
| work_keys_str_mv | AT sebastianschade cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT utekoenig cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT ardianmekolli cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT jochengaedcke cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT albrechtneesse cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT johannareinecke cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT mariusbrunner cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT aliseifamirhosseini cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT juliakitz cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT philippstroebel cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT joachimlotz cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT michaelghadimi cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT volkerellenrieder cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab AT alexanderkoenig cureispossibleextensivelymetastaticher2positivegastriccarcinomawith5yearsofcompleteremissionaftertherapywiththeflotregimenandtrastuzumab |